Centre Hospitalier Du Pays D Aix Centre Hospitalier Intercommunal Aix-Pertuis — Clinical Trial Site

38 Registered trials

19 Currently recruiting

Organisation

Centre Hospitalier Du Pays D Aix Centre Hospitalier Intercommunal Aix-Pertuis

Location

Aix En Provence, France

Identifier

ORG-100046299

Address

Avenue Des Tamaris, 13100, France

Departments

1816 :Rhumatologie
1816: Rheumatology
anesthésie-réanimation
Cardiology/EP
Gastroenterology
Hematology
hematology and oncology
Hematology Department
Maladies respiratoires
Médecine interne - Rhumatologie
medecine neonatale
Médecine physique et réadaptation
Neurology
ONCO HEMATOLOGIE MEDECINE INTERNE
Onco-hematology
Oncologie
Oncology
Pneumology
Pneumology Oncology
Réanimation polyvalente
Respiratory disease
Respiratory Diseases
Respiratory Diseases Service
Respiratory medicine
Rhumatology
Service de Neurologie
Service de Pneumologie
Service de Pneumologie et d'Allergologie
Service des maladies respiratoires

Clinical trials at this site (38)

Search interface

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APP… Pending

2024-516570-30-00 Relapsed/refractory T-cell Acute Lymphoblastic Leukemia 4
“Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicen… Pending

2024-520414-21-00 Adult patients with a LVOS with large core within 9 hou 5
BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/… Pending

2025-524289-56-00 Asthma 6
A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso… Recruiting

2024-511855-16-00 Onco-hematology 5 2019-07-25
eValuating the efficacy and safety of InitiatinG depemokImab earLy therApy iN COPD with Type 2 inflammation (VIGILANT) Recruiting

2025-521108-23-00 Chronic Obstructive Pulmonary Disease 5 2026-05-19
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 Colon carcinoma 5 2026-05-07
A Study to evaluate the long-term safety and tolerability of tozorakimab in patients with chronic obstructive pulmonary disease (COPD) and a… Recruiting

2025-523690-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2026-05-04
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting

2024-519208-29-00 Pleural mesothelioma 4 2026-04-02
Systematic Adjunction of Vasopressine in hyperkinetic Septic Shock patients: a prospective, randomized, double blind study. Recruiting

2024-513401-31-00 Septic shock 5 2026-03-24
GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran… Recruiting

2024-511437-35-00 Patients aged 18-65 years old with newly diagnosed prev 10 2026-01-05
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study) Recruiting

2024-518385-26-01 Polymyalgia Rheumatica (PMR) 5 2025-12-18
A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best in… Recruiting

2024-517018-14-00 Advanced non-small cell lung cancer 4 2025-11-17
SUPPRESS. Prophylactic frequent premature ventricular complexeS sUPPression on left ventriculaR function impairmEnt in aSymptomatic patientS Recruiting

2024-516372-14-00 Asymptomatic Patients with frequent PVCs and normal LVE 11 2025-01-13
Free regimen of Dexamethasone as initial therapy for advanced relapsed/refractory multiple myeloma: an open-label randomized, non-inferiorit… Recruiting

2024-510981-18-00 Multiple Myeloma Multiple myeloma (MM) is a B cell mali 5 2024-12-12
OPEN-LABEL PHASE II EFFICACY STUDY OF REPOTRECTINIB IN FRAIL (PS ≥2) AND /OR ELDERLYPATIENTS WITH ROS1-REARRANGED ADVANCED NSCLC Recruiting

2023-509073-23-00 Stage III/IV non-small-cell lung cancer (NSCLC) harbori 4 2024-10-01
Linezolid or vancomycin surgical site infection prophylaxis LOVip Recruiting

2023-504986-22-00 surgical antibiotic prophylaxis 5 2024-09-30
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 colon carcinoma 5 2024-08-14
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
FIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and … Recruiting

2023-506590-35-00 Large-Cell NeuroEndocrine Carcinoma of the lung 4 2024-06-13
PRODIGE 87 FOXTROT II : Personalising and refining neo-adjuvant chemotherapy in locally advanced but resectable colon cancer in the elderly … Recruiting

2023-505214-23-00 colon carcinoma 5 2024-06-07
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Patients With Stage III Unresectabl… Recruiting

2023-506891-28-00 The target population of interest in this study is part 5 2022-05-02
Neonatal hypoxic ischemic encephalopathy : safety and feasibility study of a curative treatment with autologous cord blood stem cells (NEOST… Recruiting

2024-516421-30-00 Neonatal hypoxic-ischaemic encephalopathy 4 2020-02-05
A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu… Ended

2023-508077-85-00 Polymyalgia Rheumatica 5 2024-11-19
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26